ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / LUCD / news
NYXH (45) MBOT (29) LNSR (18) QTEX (36) ⌘ Pro Terminal →

Why LUCD Stock advanced +0.37% Today — RQD Quant Desk Flash

$0.41 +0.37% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.41

Lucid Diagnostics Inc. (LUCD) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $82.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LUCD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LUCD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Lucid Diagnostics Inc. (NASDAQ: LUCD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $0.41 (+0.37% 1D, market cap $82.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, LUCD ranks #486 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LUCD compare to NYXH and MBOT in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), LUCD carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NYXH (Nyxoah SA) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $87.2M) and MBOT (Microbot Medical Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -15.8%, cap $73.2M). Among the 5-stock peer group, LUCD leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LUCD?
▼

Per LUCD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001799011), Lucid Diagnostics Inc. generated $139.0M in revenue (+3098.2% YoY), -$58.0M in net income, and -$46.7M in free cash flow against $40.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.41 (-0.12%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510039
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (7)Whales (8)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.8% Base Target
$2 Bull$0 Base$0 Bear
📬 FREE LUCD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LUCD)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (39/100 Composite)
🔍 WHY LUCD SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (23% of score)

FRED Regime × Technicals: 8% of 52W Range • RSI-14 at 35.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
47
Grade D$0.60-36.7% Next Q
Q2 (-2Q)
44
Grade D$0.38+31.6% Next Q
Q3 (-1Q)
42
Grade D$0.50-18% Next Q
Current
39
Grade D-$0.41-7.6% Hist 90D α
Trajectory: D (47) → D- (39)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LUCD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LUCD currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.70) and Max Pain ($0.43) forces dealer call-delta covering toward $1.71.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LUCD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LUCD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 39%NO 61%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why LUCD Stock advanced +0.37% Today — RQD Quant Desk Flash

Lucid Diagnostics Inc. (LUCD) advanced +0.37% to $0.41, trading at 8% of its 52-week range ($0.3 – $1.63). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 8% of its 52-week range ($0.3 – $1.63) with RSI-14 at 35.4 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.41 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live LUCD Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LUCD)

  • ✓Walkthrough of LUCD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LUCD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -62.39%▼ DESCENDING CHANNEL
2026-11-03O $0.43H $0.43L $0.40C $0.41VOL 1.71M
RES: $0.72SUP: $0.22SMA50: $0.70SMA200: $1.02
$1.34$1.06$0.78$0.49$0.21RES $0.72SUP $0.22$0.412026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LUCD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LUCD Butterfly Map → + Track LUCD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +3098.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LUCD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LUCD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LUCD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LUCD)

Health Care Rank #486 of 1015 ⚔️ NYXH vs LUCD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LUCD vs. NYXH, MBOT, LNSR, QTEX)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Lucid Diagnostics Inc. (LUCD) ranks #486 by composite RQD confidence (39/100, grade D-) and #677 by equity capitalization ($82.3M). Within this direct 5-issuer industry benchmark cohort, LUCD leads on earnings valuation at N/A trailing P/E, while MBOT leads on capital efficiency and profitability with -15.8% ROIC and — gross margin. NYXH currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with LUCD at 39/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LUCD ACTIVE
Lucid Diagnostics Inc.
D- 39/100 — — -35.0% +0.37% $82.3M Benchmark Subject
NYXH
Nyxoah SA
D 45/100 — — — +0.99% $87.2M /nyxh-vs-lucd →
MBOT
Microbot Medical Inc.
E 29/100 — — -15.8% -4.59% $73.2M /mbot-vs-lucd →
LNSR
LENSAR Inc.
E 18/100 — 39.4% -35.0% -2.91% $71.7M /lnsr-vs-lucd →
QTEX
QTREX Quantum Ltd.
D- 36/100 — 0.7% -35.0% -8.20% $68.3M /qtex-vs-lucd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001799011 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lucid Diagnostics Inc. (LUCD) reported GAAP revenue of $139.0M (+3098.2% vs. FY2024 revenue of $4.3M , and +5624.5% cumulative change since FY2023) , GAAP net income of -$58.0M, operating cash flow of -$46.5M, and free cash flow of -$46.7M (-5.1% YoY). On the balance sheet, LUCD closed FY2025 with $40.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $139.0M -$58.0M -$46.5M -$46.7M $40.4M —
FY2024 (FY) 2024-12-31 $4.3M -$45.5M -$44.1M -$44.4M $30.7M —
FY2023 (FY) 2023-12-31 $2.4M -$52.7M -$32.8M -$32.8M — —

3. LUCD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LUCD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Lucid Diagnostics Inc. (NASDAQ: LUCD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $0.41 (+0.37% 1D, market cap $82.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, LUCD ranks #486 in composite RQD confidence.

How does LUCD compare to NYXH and MBOT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), LUCD carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NYXH (Nyxoah SA) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $87.2M) and MBOT (Microbot Medical Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -15.8%, cap $73.2M). Among the 5-stock peer group, LUCD leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LUCD?

Per LUCD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001799011), Lucid Diagnostics Inc. generated $139.0M in revenue (+3098.2% YoY), -$58.0M in net income, and -$46.7M in free cash flow against $40.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LUCD trading relative to its 50-day, 200-day, and 52-week technical levels?

LUCD last traded at $0.41 (+0.37% on volume of 1,351,883 shares), positioning the stock -41.43% below its 50-day simple moving average ($0.70) and -59.80% below its 200-day simple moving average ($1.02). Across its 52-week range of $0.30 to $1.63, LUCD sits at the 8.3% percentile with a 14-day RSI of 35.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.46).

Direct Sub-Reports: LUCD RQD Cockpit LUCD 12M Forecast LUCD Earnings & Move LUCD Dividends & DRIP LUCD Insiders & 13F LUCD Whale Options LUCD Profit Sankey LUCD News & Why
ROARABLE RATING BRIEF • RQD 39/100 (D-) ✓ SEC XBRL & RQD VERIFIED

LUCD — Lucid Diagnostics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Lucid Diagnostics Inc. (LUCD) earns a live Roarable RQD composite score of 39/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.41 (+0.37% 1D, market capitalization $82.3M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Lucid Diagnostics Inc. Is a NASDAQ-listed issuer in the Health Care sector and the Medical/Dental Instruments industry. The profile does not describe its products, customers, or revenue model. Revenue reported in the SEC financials is — for FY 2025, $4.3M for FY 2024, and $2.4M for FY 2023.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Lucid Diagnostics Inc. (LUCD) reported $139.0M in annual revenue (up from $4.3M in FY2024, +3098.2% YoY) and -$58.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.4M revenue, -$52.7M net income) through FY2025, LUCD scaled operating cash flow to -$46.5M and free cash flow to -$46.7M, backed by $40.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 39/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 8/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $0.30 – $1.63 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), LUCD carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can LUCD sustain or expand its — operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $139.0M and free cash flow of -$46.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is LUCD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LUCD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Lucid Diagnostics Inc. (LUCD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LUCD Debate Forum (3) ↓
🟡 MARKET WIRE Benzinga • 11h ago
PAVmed Unit Lucid Diagnostics Announces Publication Of Clinical Findings From Nonendoscopic Esophageal Precancer Testing Using The EsoGuard; Study Demonstrates Efficiency And Scalability Of EsoCheckCell Collection In Under Two Minutes

The manuscript, "Non-Endoscopic Screening for Barrett's Esophagus Using a DNA Methylation-Based Assay: Real-World Experience in 11,991 Patients," published in the journal Diagnostics, reported that EsoCheck

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LUCD Bull vs. Bear Conversation Board — What's Your Call at $0.41?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LUCD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LUCD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $0.53 (+32.5%)
📌 Pinned Debate

Institutional accumulation and options positioning score 15 / 20 in the RQD rating, and Medicare reimbursement for EsoGuard® has begun

Long LUCD at $0.40 targeting $0.53. Institutional accumulation and options positioning score 15 / 20 in the RQD rating, and Medicare reimbursement for EsoGuard® has begun alongside a $15 Million financing close.. Institutional whale score is 8/20 and the risk/reward vs. the $0.30 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader 🐂 BULL

@CreditSpread_Watch Shorting a 8/20 institutional whale-flow stock at $0.40 is dangerous when funds are rotating into Health Care.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $0.32 (-20.0%)
Spot @ $0.40

ROIC of -35%, FCF of -$46.7M in FY 2025, and a Nasdaq minimum bid price noncompliance notice at a price of 0.4 show a cash engine that

Sitting on the sidelines or leaning short LUCD above $0.40. ROIC of -35%, FCF of -$46.7M in FY 2025, and a Nasdaq minimum bid price noncompliance notice at a price of 0.4 show a cash engine that is not yet self-funding.. Until Fundamental Cash Engine (7/20) and FCF yield (0.0%) inflect higher, upside is capped near $1.63.

LIVE TAPE